Concluding Thoughts on Biosimilars in Multiple Sclerosis
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.
Biosimilar Discussion With Patients and Biosimilar Resources
Advanced practice providers share how to discuss biosimilars with patients and what resources might be useful for education on biosimilars.
Implementing Biosimilars in Clinical Practice
Amy Perrin Ross, APN, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share strategies for implementing biosimilars in clinical practice.
Access to and Challenges to Biosimilar use in Clinical Practice
John Kramer, PA-C, Patricia Melville, NP-C, and Amy Perrin Ross, APN identify challenges in accessing biosimilars in clinical practice.
Comparison of AFFIRM (Reference Natalizumab) and Antelope (Biosimilar Natalizumab) Trials
Aliza Ben-Zacharia, PhD, DNP, ANP-BC and Amy Perrin Ross, APN discuss differences between biologic and biologic natalizumab phase 3 trials.
Natalizumab Biosimilar in Development in Multiple Sclerosis
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss natalizumab biosimilar (biosim-NTZ) PB006 phase 3 Antelope study.
Cost Savings with Biosimilars and Use in Multiple Sclerosis
Advanced practice providers discuss potential cost savings with biosimilars and biosimilar use in multiple sclerosis.
Immunogenicity of Biosimilars
Amy Perrin Ross, APN, Patricia Melville, NP-C, and Aliza Ben-Zacharia, PhD, DNP, ANP-BC discuss importance of evaluating immunogenicity of biosimilars.
Approval Process for Biosimilars
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss approval process of biosimilars.
Comparison of Biosimilar Products and Reference Products
Clinical experts discuss differences and similarities between biosimilars and reference products.
What is a Biosimilar?
Four advanced practice providers discuss biosimilars and how they can play an important role in healthcare.
Managing MS in the Community: Advice and Resources
Advice and resources for colleagues, including community practitioners and neurologists, to encourage collaboration and best support for patients with multiple sclerosis (MS).
Looking Ahead at Managing MS
An optimistic look at the future management of multiple sclerosis (MS) based on newer treatment options and ongoing research in the field.
Lifestyle Interventions to Manage MS
Recommendations surrounding the use of complementary and natural therapies to manage symptoms of multiple sclerosis (MS).
Sequencing Therapies in RRMS
Best practices for establishing treatment plans for patients with relapse-remitting multiple sclerosis (RRMS) and making decisions to switch therapies based on inadequate treatment responses, relapse, or disease progression.
Fumarates for Relapsing MS
An overview of fumarates available as treatment for relapsing multiple sclerosis and recommendations for counseling and caring for patients on these therapies.
Anti-CD20 Utilization in Relapsing MS
Considerations for using anti-CD20 therapies versus other available treatment options for relapsing multiple sclerosis.
Anti-CD20 Therapies for Relapsing MS
An overview of clinical trial data supporting the use of ocrelizumab and ofatumumab as treatment options for patients with relapsing multiple sclerosis.
Selecting an S1P Modulator for Relapsing MS
Variables that impact which S1P receptor modulator is selected as treatment for relapsing multiple sclerosis.
S1P1 Receptor Modulators for Relapsing MS
Bryan Walker, MHS, PA-C, describes the rationale for treating relapsing multiple sclerosis (MS) with sphingosine 1-phosphate (S1P1) receptor modulators and compares available options.
Clinical Experience Treating Relapsing MS With Cladribine
Best practices for treating patients with relapsing multiple sclerosis (MS) with cladribine, based on data revealed by clinical trials and experience in real-world practice.
Risk of Relapse/Progression in MS
A discussion on the integration of newer therapies, like cladribine, into the treatment landscape for relapsing multiple sclerosis (MS), and insight regarding what is currently understood about risks of disease progression and relapse.
Cladribine Treatment for Relapsing MS
An overview of clinical trial data supporting the use of cladribine as treatment for relapsing multiple sclerosis (MS).
Interferons and Glatiramer Acetate for Relapsing MS
Health care professionals who work in the field of neurology comment on their experience using interferon therapies and glatiramer acetate as treatment for relapsing multiple sclerosis.
Overcoming Treatment Challenges in Relapsing MS
The rationale for early treatment of multiple sclerosis, and an overview of limitations that impact the management of relapsing multiple sclerosis.
Tailoring Therapy for Patients With Relapsing MS
Important insight related to individualized treatment approaches for patients with relapsing multiple sclerosis.
Revised Recommendations for Diagnosing Relapsing MS
An overview of revisions to the McDonald criteria used to help diagnose relapsing multiple sclerosis, and recommendations to follow when referring to criteria and imaging results when evaluating patients.
2 Clarke Drive Cranbury, NJ 08512